CompletedNot Applicable

ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)

South Korea3,612 participantsStarted 2012-11

Plain-language summary

This is an open label, multi-centre, non-interventional post-marketing surveillance.

Age range9 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Subjects administered with ALTARGO(retapamulin) in the topical treatment of the following bacterial skin and skin structure infections (SSSI)
✓. Subjects who the investigator believes that they can and will comply with the requirements of the protocol and follow the administration regimen
✓. Subjects administered with ALTARGO(retapamulin) following the locally approved prescribing information

✕. Subjects with a known or suspected hypersensitivity to ALTARGO(retapamulin) or any component of the ointment
✕. Infants under nine months of age

The number of adverse event after ALTARGO(retapamulin) treatment

Timeframe: 14 days

NCT IDNCT01445600

SponsorGlaxoSmithKline

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2015-08